PD-1抗体联合安罗替尼及^(125)I粒子链置入治疗肝门部胆管癌的疗效初探(附3例分析)

Preliminary Study on the Efficacy of PD-1 Antibody Combined with Antirotinib and ^(125)I seed Chain Implantation in the Treatment of Perihilar Cholangiocarcinoma(Analysis of 3 Cases)

目的探讨PD-1抗体联合安罗替尼及^(125)I粒子链置入治疗肝门部胆管癌的初步疗效及安全性。方法回顾性分析3例肝门部胆管癌患者的临床资料,均经病理结合实验室检查及影像学检查确诊,在DSA引导下行经皮肝穿胆道造影术,置入胆道支架及^(125)I粒子引流管,后续配合替雷利珠单抗及安罗替尼规律治疗。结果3例患者手术均成功,粒子引流管有效覆盖胆管病变区域,配合替雷利珠单抗及安罗替尼等药物治疗后病情均得到有效控制。结论替雷利珠单抗联合安罗替尼及^(125)I粒子链置入治疗肝门部胆管癌安全有效。

Objective To investigate the initial efficacy and safety of PD-1 antibody combined with antirotinib and^(125)I seed chain implantation in the treatment of perihilar cholangiocarcinoma.Methods Clinical data of 3 patients with perihilar cholangiocarcinoma admitted to our department from April to January 2021 were retrospectively analyzed.All of them were confirmed by pathology combined with laboratory examination and imaging examination.Under the guidance of DSA,percutaneous transhepatic cholangiography was performed,biliary stent and^(125)I particle drainage tube were inserted,and then regular treatment was performed with tirelizumab and anrotinib.Results All the three patients were successfully operated.Particle drainage tube effectively covered the diseased area of bile duct,and the disease conditions were effectively controlled after treatment with tiralizumab and anrotinib.Conclusion Tirelizumab combined with allotinib and^(125)I seed chain implantation is safe and effective in the treatment of perihilar cholangiocarcinoma.